A research team led by Professor Chen Peng from the College of Chemistry and Molecular Engineering at Peking University has ...
A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and identifies a new combination treatment. Publishing in Nature Immunology, ...
New research reports the creation of a degradation-based cancer vaccine that penetrates tumor cells and converts them into ...
Immune checkpoint inhibitors have revolutionized cancer treatment, yet many tumours develop strategies to evade or suppress immune responses, limiting long-term efficacy. This webcast will examine how ...
Among modern cancer therapies, immune checkpoint inhibitors (ICI) are among the most successful treatment methods. These ...
In a study published in the journal Biofunctional materials, researchers from the Wits Advanced Drug Delivery Platform (WADDP) Research Unit, Department of Pharmacy and Pharmacology, and the Division ...
Patients who are prescribed antibiotics during immune checkpoint blockade therapy for solid tumors face a heightened risk for ...
Niraparib in patients with BRCA-mutated unresectable or recurrent biliary tract, pancreatic and other gastrointestinal cancers: An investigator-initiated phase 2 trial (NIR-B trial). This is an ASCO ...
Initial Dose Adjustment of Zolbetuximab Plus Chemotherapy in CLDN18.2-Positive Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer (GENTLE-Z), a Randomized, Phase II Trial ...
Researchers have shown HIF1α as a key regulator that induces the cancer-killing capacity of T cells in hypoxic conditions. A team of researchers from the University of Alabama at Birmingham (AL, USA) ...
A research team led by Professor Chen Peng from the College of Chemistry and Molecular Engineering at Peking University has developed a novel cancer immunotherapy strategy that forces tumors to expose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback